期刊文献+

促凋亡蛋白PDCD5在卵巢上皮性癌中的表达及其与生存关系的研究 被引量:3

Expression of PDCD5 protein in epithelial ovarian cancer and it's relationship with survival
下载PDF
导出
摘要 目的探讨促凋亡蛋白PDCD5(Programmed Cell Death 5)在卵巢上皮性癌组织中的表达及其与患者生存时间的关系。方法收集手术切除的卵巢癌组织107例,卵巢良性肿瘤组织16例和正常卵巢组织11例。采用免疫组织化学方法检测各组织内PDCD5蛋白的表达。利用图像分析系统和图像分析软件测定PDCD5蛋白在卵巢上皮性癌、卵巢良性肿瘤及正常卵巢组织中表达的平均光密度值,并结合临床资料进行生存分析。结果①正常卵巢组织,卵巢良性肿瘤组织中PDCD5蛋白呈高表达;卵巢癌组织中PDCD5蛋白呈低表达;图像分析结果显示三组间差异有统计学意义(P<0.05);②PDCD5蛋白在不同FIGO分期和组织学分级的卵巢上皮性癌中表达有显著差异(P<0.05),并且随着FIGO分期和组织学分级的升高,PDCD5蛋白的表达下降;③PDCD5蛋白表达强弱与患者生存时间呈正相关(P<0.05,R=0.731)。结论PDCD5蛋白与卵巢上皮性癌的发生、发展及临床预后有密切关系。 Objective To explore the expression level of Programmed Cell Death 5(PDCD5)protein in epithelial ovarian cancer tissues and to clarify the relationship between PDCD5 and survival time .Methods The expression of PDCD5 protein was analyzed by immunohistochemistry in 107 cases of epithelial ovarian cancer,16 cases of benign ovarian neoplasma and 11 cases of normal ovarian tissues.The image analysis system was used to measure the average optical density.The correlation of PDCD5 protein and patients' survival time was analyzed.Results ①PDCD5 protein expression was higher in normal ovarian tissues and benign ovarian neoplasma, but lower in epithelial ovarian cancer tissues.Image analysis demonstrated that the expression of PDCD5 protein among the three groups had significant statistical differences (P0.05).②The expression of PDCD5 protein in different FIGO stages and histological grades of epithelial ovarian cancer tissues had significant statistical differences(P0.05), and were downregulated with the increasing of FIGO stages and histological grades.③There was strongly positive correlation between the expression of PDCD5 protein and the survival time (P0.05,R=0.731).Conclusions The PDCD5 protein has a close relationship with the occurrence, development and clinical prognosis of epithelial ovarian cancer.
出处 《中国妇产科临床杂志》 2012年第1期46-49,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 北京市自然科学基金(7092108) 博士点课题(801986)
关键词 卵巢上皮性癌 PDCD5蛋白 免疫组织化学 生存时间 epithelial ovarian cancer PDCD5 protein immunohistochemistry survival time
  • 相关文献

参考文献4

二级参考文献27

  • 1冯静,崔恒,魏丽惠,马大龙.TFAR19蛋白在卵巢上皮性癌中的表达[J].中国妇产科临床杂志,2002,3(3):164-167. 被引量:23
  • 2张岱,刘朝晖,李克敏,范慧,廖秦平.重组人PDCD5蛋白对干扰素γ诱导人宫颈癌SiHa细胞凋亡的增敏作用的初步探讨[J].中国妇产科临床杂志,2004,5(4):286-289. 被引量:14
  • 3谭万龙,熊林,郑少斌,郁兆存,齐桓,杜跃军,吴芃.肾透明细胞癌PDCD5表达及与预后的关系[J].南方医科大学学报,2006,26(9):1316-1318. 被引量:24
  • 4刁鑫伟,叶明福,陈正堂,张哉根,王亚丽.113例前列腺癌AR与凋亡相关因子表达的研究[J].重庆医学,2007,36(6):518-520. 被引量:5
  • 5[1]Hongtao Liu, Yugang Wang, Yingmei Zhang, et al. TFAR19, a novel apoptosis- related gene cloned from human leukemia cell line TF - 1,could enhance apoptosis of some tumor cells induced by growth factor withdrawl. Biochem Biophy Res Comm, 1999, 254:203-210
  • 6[10]连丽娟,主编,林巧稚妇科肿瘤学,第2版.北京:人民卫生出版社,1994
  • 7Yasui H, Hideshima T, Richardson PG, et al. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol, 2006;132(4) :385 -397.
  • 8Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol, 2004 ;5 (7) :430-442.
  • 9Greipp PR, San Miguel J, Durie BG, et al. International Staging System for Multiple Myeloma. J Clin Oncol, 2005 ;23 (15) :3412 - 3420.
  • 10Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006 ; 20 ( 9 ) : 1467 - 1473.

共引文献54

同被引文献34

  • 1范嫏娣.卵巢浆液性交界性肿瘤的病理诊断[J].实用妇产科杂志,2005,21(10):579-581. 被引量:5
  • 2谭万龙,熊林,郑少斌,郁兆存,齐桓,杜跃军,吴芃.肾透明细胞癌PDCD5表达及与预后的关系[J].南方医科大学学报,2006,26(9):1316-1318. 被引量:24
  • 3Russo FP, Parola M. Stem cells in liver failure [J]. Best Pract Res Clin Gastroenterol, 2012, 26(1): 35-45.
  • 4Levine P, McDaniel K, Francis H, et al. Molecular mechanisms of stem cell therapy in alcoholic liver disease[J]. Dig Liver Dis, 2014, 46 (5): 391-397.
  • 5Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte trans- plantation[J]. Transplantation, 2012, 93(4): 342-347.
  • 6Vacanti JP, Kulig KM. Liver cell therapy and tissue engineering for transplantation[J]. Semin Pediatr Surg, 2014, 23(3): 150-155.
  • 7Sakai Y, Yamanouchi K, Ohashi K, et al. Vascularized subcutaneous human liver tissue from engineered hepatocyte/fibroblast sheets in mice[J]. Biomaterials, 2015, 65: 66-75[Epub ahead of print].
  • 8Lee SY, Kim HI, Choi D. Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation [J]. lnt J Stem Cells, 2015, 8(1): 36-47.
  • 9Palakkan AA, Hay DC, Anil Kumar PR, et al. Liver tissue engineering and cell sources: issues and challenges [J]. Liver lnt, 2013, 33 (5): 666-676.
  • 10Sokal EM. From hepatocytes to stem and progenitor cells for liver re- generative medicine: advances and clinical perspectives [J]. Cell Pro- lif, 2011,44 (Suppl 1): 39-43.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部